spacer
home > ebr > spring 2017 > seize the market
PUBLICATIONS
European Biopharmaceutical Review

Seize the Market

Modern biopharmaceuticals such as monoclonal antibodies (mAbs) and fusion proteins play an important role in the treatment of severe diseases, including cancer and autoimmune disorders. This market is expected to increase with a compound annual growth rate (CAGR) of 9.4% from 2015 to 2020, based on more than 280 biopharmaceuticals on the market and hundreds in clinical studies (1). In 2016, the FDA approved seven mAb drugs, three recombinant blood factors and three biosimilars (2-4). The number of approvals of new biopharmaceuticals by the EMA was in the same range (5).

The well-filled drug development pipeline of biopharmaceutical companies is the base for this notable progress, but the advancement of such complex products requires considerable effort and special expertise as well as state-of-the-art capabilities. Therefore, many firms outsource part of their activities to contract development and manufacturing organisations (CDMOs). The corresponding biopharma contract manufacturing market is predicted to grow with a CAGR of 13.4% from 2015 to 2020 (1).

Under the current market conditions, mid-size CDMOs are particularly important. They often focus on special segments like mammalian- or microbial-based development of recombinant proteins and typically provide bioreactor scales smaller than 10,000L. Most have many years of experience and offer a broad range of services and capabilities along with proprietary innovative technologies and well-established manufacturing platforms. A lot of them have expanded their capabilities in the past few years and established new stainless steel or single-use bioreactor capacities, allowing them to act with a high degree of flexibility in manufacturing for various clinical phases and for market supply.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Stefan R Schmidt, MBA, currently serves as Senior Vice President at Rentschler Biotechnologie, Germany, and is responsible for the process science and manufacturing of biopharmaceuticals to current Good Manufacturing Practice standards. He previously held the position of Chief Scientific Officer at ERA Biotech, directing the company’s R&D efforts focusing on fusion peptides. Prior to that, Stefan worked at AstraZeneca where he led the unit of Protein Sciences as Associate Director. In the past 10 years, he has been intensively involved with fusion proteins, publishing the first comprehensive book on the topic in 2013.

Dr Birgit Schwab is Marketing Manager at Rentschler Biotechnologie, responsible for the market research including market, competitive and client analysis as well as conducting surveys. She studied Chemistry in Dresden, Germany, and completed her PhD in the area of Analytical and Theoretical Chemistry. Since 2004, Birgit has been working at Rentschler in Sales and Marketing and has been involved in different fields such as proposal management and sales controlling. 
spacer
Dr Stefan R Schmidt
spacer
spacer
spacer
Dr Birgit Schwab
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck to Provide Provantage® End-to-End Services to Acticor Biotech SAS


More info >>

White Papers

Technology Solutions - Driving efficiencies, quality and operational excellence

Worldwide Clinical Trials Ltd

Clinical trials involve the entry, analysis and reporting of millions of pieces of data; year-on-year, the amount of data required to manage efficacy and safety increases exponentially. Recently, solutions available to support this activity have grown in numbers and complexity. The rise of Tablets and Smart Phones combined with the growth of Cloud or SAS solutions has resulted in the technology landscape required to support complex, global studies becoming more confusing.
More info >>

 
Industry Events

7th American Drug Delivery & Formulation Summit

28-29 August 2017, The Westin Copley Place Boston Hotel

Innovative solutions to the greatest challenges in pharmaceutical development
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement